Search
Anagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigationalAnagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. … [A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: ANAGRELID RATIO 1 MG, Anagrelid Nordic 1 mg TablettenSomatotropin
go.drugbank.com/drugs/DB00052ApprovedInvestigational[A228188] Recombinant HGH has been commercially available since 1985 after its development by Genentech. … [A228183, L31508] Synthesized in a strain of _Escherichia coli_, recombinant HGH is a polypeptide hormone that contains 191 amino acid residues with a molecular weight of 22 kDa.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersProducts: SAIZEN 4 IU FLAKON, 1 ADET, SAIZEN®6 MG /1.03ML( 5.83MG/ML)Givosiran
go.drugbank.com/drugs/DB15066ApprovedGivosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder
Categories: Heterocyclic Compounds, 1-Ring, Aminolevulinate Synthase 1-directed RNA InteractionIxekizumab
go.drugbank.com/drugs/DB11569ApprovedInvestigationalIn particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. … Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor.
Products: COPELLOR 80 MG/1 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET, COPELLOR 80 MG/1 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADETOBE101
go.drugbank.com/drugs/DB05080ExperimentalOBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. … Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.
Succinic acid
go.drugbank.com/drugs/DB00139ApprovedInvestigationalNutraceuticalIt is also used in foods as a sequestrant, buffer, and a neutralizing agent. … A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters.
Mixtures: Se-Vate 21/7, FeRiva 21 7Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigational(IL-6) blockers, and tumor necrosis factor (TNF) inhibitors. … [A189165] New therapeutic developments target other inflammatory pathways implicated in RA including the Janus kinase (JAK) signaling pathway as seen with filgotinib.
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingOxybutynin
go.drugbank.com/drugs/DB01062ApprovedInvestigationalOveractive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. … [A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and
Synonyms: 4-Diethylamino-2-butinyl alpha-cyclohexylmandelat, 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolateCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsLisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigationalLisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel]. … [A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4.
Categories: Antineoplastic cell and gene therapy, CD19-Directed Genetically Modified Autologous T-cell ImmunotherapiesCrizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigationalCrizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement
Categories: Receptor Tyrosine Kinase Inhibitors, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: (R)-crizotinib